Generative AI Reshapes B2B Buying Decisions

Generative AI is changing B2B buying by moving discovery, evaluation, and recommendation into AI-mediated environments that suppliers do not own, the Harvard Business Review reports. The HBR article illustrates the effect with an oncology scenario where a newly approved drug with strong trial results appears less prominently in an AI assistant's synthesized answer than an earlier entrant with more public discussion and real-world evidence, according to HBR. HBR reports that the clinical decision-support assistant OpenEvidence is used daily by more than 40% of U.S. physicians, per the company's internal numbers cited in the article. The story says platform usage rose about sevenfold from approximately 2.6 million sessions in December 2024 to a much larger January 2026 total, as reported in HBR. The article also states that OpenAI and Anthropic increased focus on healthcare in early 2026, according to HBR.

Industry-pattern observations: AI-mediated discovery depends on retrieval quality, index coverage, and the availability of machine-readable, evidence-rich content. For practitioners, that raises engineering priorities around structured data, metadata, and formats that improve algorithmic prominence in synthesis and ranking. Techniques commonly used in the field include retrieval-augmented generation (RAG), embedding-based nearest-neighbor search, and document-level provenance tracking; these approaches change how product, medical-affairs, and technical-communications teams think about packaging evidence.

The HBR report places this effect across B2B sectors such as pharmaceuticals and manufacturing, arguing that AI assistants are becoming durable parts of professional workflows rather than experimental tools. For practitioners building models, search stacks, or content pipelines, the practical implication is that public-facing documentation and evidence must be optimized for retrieval and machine consumption if it is to influence synthesized outputs. This is not limited to healthcare; any domain where decision-support assistants synthesize recommendations will privilege sources that are discoverable and structured for machine reading.

• •Metrics: adoption and query volume trends for vertical assistants, and measured impacts on downstream decisions and procurement choices, as reported by vendors or audited third parties.
• •Data strategy signals: whether organizations publish more machine-readable summaries, structured evidence tables, or standardized metadata to improve algorithmic retrieval.
• •Regulatory and auditability developments, especially in regulated sectors like healthcare, where provenance and explainability are likely to attract scrutiny.

Editorial analysis: Practitioners should treat this as a shift in where influence is exercised. Rather than only controlling direct sales channels, organizations now need to consider how their public evidence and metadata interact with third-party synthesis engines. This is an industry-wide pattern, not a claim about any single firm's internal priorities or roadmap.